Intensive LDL lowering with evolocumab reduced first heart attack or stroke in diabetes
Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known atherosclerosis (the build-up ...
Mar 29, 2026
0
8









